Revolutionizing Stem Cell Research: ACROBiosystems’ DLL4
ACROBiosystems, a pivotal player in the pharmaceutical industry, recently announced the launch of its GMP grade DLL4, a significant advancement in the field of stem cell research and biologics manufacturing. DLL4, or Delta-like Ligand 4, is a recombinant, soluble protein now available in a GMP (Good Manufacturing Practice) compliant form. This launch marks a considerable […]
Revolutionizing Treatment: Century Therapeutics and FUJIFILM’s Groundbreaking Alliance to Combat Autoimmune Diseases with Stem Cell Therapies
In a significant development for the treatment of autoimmune and inflammatory diseases, Century Therapeutics, Inc., a trailblazing biotechnology company, and FUJIFILM Cellular Dynamics, Inc., a prominent developer and manufacturer of human induced pluripotent stem cells (iPSCs) and iPSC-derived cells, have announced a worldwide license agreement. This collaboration is set to advance the development and commercialization […]
Synthetic Embryos: Ethical Dilemma or Medical Breakthrough?
In a groundbreaking exploration of the boundaries of life and technology, scientists at the Weizmann Institute of Science in Israel have made a significant leap forward in the field of embryology. The research team, led by Jacob Hanna, has successfully reprogrammed stem cells to form structures strikingly similar to human embryos, a feat that could […]
Garuda Wins Big: Revolutionizing Stem Cell Therapy
Garuda Therapeutics has been honored with the prestigious title of “Overall Cell Biology Company of the Year” by BioTech Breakthrough, an independent organization that recognizes top performers in the life sciences and biotechnology sectors. This accolade was awarded to Garuda for their innovative approach to creating off-the-shelf hematopoietic stem cell (HSC) therapies. These therapies are […]
Avid Bioservices Partners with California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
Avid Bioservices, a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it has partnered with the California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, to provide contract development and manufacturing (CDMO) services for cell and gene therapy (CGT) programs funded by CIRM. Through this partnership, Avid will make its CGMP […]
Tract Bio Unveils Key to CF Lung Inflammation
Tract Bio, a biotechnology company focused on developing therapies for cancer and inflammatory diseases, has recently announced a significant publication in the American Journal of Respiratory and Critical Care Medicine. The publication details their research on stem cell variants that contribute to chronic lung inflammation in cystic fibrosis patients treated with CFTR modulators. Key Highlights […]
Revolutionary ExoPTEN Therapy: FDA’s New Hope for Spinal Injuries
NurExone Biologic Inc., a leading biotechnology company, has recently achieved a significant milestone in the development of treatments for acute spinal cord injuries. The U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) to the company’s innovative ExoPTEN therapy. This designation is crucial for conditions like acute spinal cord injury, where effective treatments […]
Revolutionizing Cystic Fibrosis: DNA Tech Breakthrough
Moligo Technologies has entered into a collaboration with Nationwide Children’s Hospital to provide long, single-stranded DNA (ssDNA) for research into gene therapies for cystic fibrosis (CF) and other airway diseases. Moligo’s innovative enzymatic DNA production technology produces ultrapure, long ssDNA at an industrial scale. This technology is especially promising as it can introduce chemical modifications, […]
Neurona Therapeutics’ Progress in Phase I/II Clinical Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Ep
Neurona Therapeutics, a clinical-stage biotherapeutics company, recently announced the completion of enrollment for the first cohort in its ongoing Phase I/II clinical trial of NRTX-1001. This investigational allogeneic cell therapy is being developed to treat drug-resistant mesial temporal lobe epilepsy (MTLE). The first cohort consisted of five subjects who received a one-time dose of NRTX-1001, […]
Coeptis Therapeutics Expands Collaboration with University of Pittsburgh on CAR NK Cell Therapy
Biotech startup Coeptis Therapeutics announced an expanded partnership with the University of Pittsburgh today, licensing additional CAR NK cell therapy technology developed at Pitt. This new agreement builds on their existing collaboration around a CD19-targeting CAR NK cell therapy for blood cancers. The new technology, known as SNAP CAR NK cells, allows for more precise […]